Interstitial Fluid Sampling Device
20230077165 · 2023-03-09
Inventors
Cpc classification
A61B5/14514
HUMAN NECESSITIES
International classification
Abstract
A device for extracting an interstitial fluid sample from the skin of a mammal subject is disclosed. The device comprises at least one micro-needle comprising a tip portion configured to be inserted into the skin of the mammal subject, and a passage configured to transport the interstitial fluid from the skin to a retaining material arranged in a channel of a body of the device. The retaining material is fluidically connected to the passage and configured to absorb and store the interstitial fluid sample transported by the passage. A holder configured to receive such a device is also disclosed.
Claims
1-17. (canceled)
18. A device for extracting an interstitial fluid sample from the skin of a mammal subject, comprising: at least one micro-needle comprising a tip portion and a passage, wherein the tip portion is configured to be inserted into the skin of the mammal subject, and wherein the passage is configured to transport the interstitial fluid sample, extracted from the skin by the at least one micro-needle, away from the tip portion; a body configured to support the at least one micro-needle; and a retaining material arranged in a channel of the body; wherein the retaining material is fluidically connected to the passage and configured to absorb and store the interstitial fluid sample transported by the passage, and wherein the retaining material abuts an end portion of the passage, or wherein the passage at least partly extends into the retaining material.
19. The device according to claim 18, wherein the at least one micro-needle protrudes from the body such that the tip portion penetrates the skin in response to the body being placed on the skin.
20. The device according to claim 18, wherein the retaining material at least partly overlaps a liquid meniscus formed by the filling of the passage with a fluid.
21. The device according to claim 18, wherein the retaining material is a porous material.
22. The device according to claim 18, wherein the device is configured to allow removal of the retaining material.
23. The device according to claim 18, further comprising a fill level indicator for indicating when the interstitial fluid sample stored in the retaining material reaches a predetermined volume.
24. The device according to claim 23, wherein the fill level indicator comprises a substance configured to change a colour of the interstitial fluid sample, and wherein the body comprises a window indicating a progress of the coloured interstitial fluid sample along the channel.
25. The device according to claim 24, wherein the substance is located in or on a part of the retaining material arranged upstream of the window.
26. The device according to claim 23, wherein the fill level indicator comprises an electrical or optical sensor configured to determine the fill level of the interstitial fluid sample in the retaining material.
27. The device according to claim 23, wherein the predetermined volume is 10 μl or less, such as 3 μl or less, and such as 1 μl or less.
28. The device according to claim 18, wherein a tip radius of the tip portion is 50 μm or less, such as less than 5 μm or less, and such as 1 μm or less, and wherein the needle protrudes 2000 μm or less from the body, such as 1000 μm or less, such as 500 μm or less.
29. The device according to claim 18, wherein the passage is formed by a trench extending along at least a part of the needle.
30. The device according to claim 29, wherein the trench comprises a hydrophilic structure for facilitating capillary transport of the interstitial fluid sample.
31. A holder configured to receive a device according to claim 18, wherein the holder comprises a rim portion configured to be placed on the skin and to at least partially encircle the at least one micro-needle when said at least one micro-needle is inserted in the skin, and wherein the rim portion is further configured to exert a pressure on portions of the skin adjacent to the at least one micro-needle to facilitate extraction of the interstitial fluid sample from the skin.
32. The holder according to claim 31, further comprising a resilient member configured to push the at least one micro-needle towards the skin when the rim portion is placed on the skin.
33. The holder according to claim 31, further comprising an attachment means for securing the holder to the skin.
34. A method for sampling an interstitial fluid sample from the skin of a mammal subject, the method comprising: inserting at least one micro-needle comprising a tip portion and a passage into the skin of the mammal subject, transporting the interstitial fluid sample through the passage away from the tip portion, absorbing and storing the interstitial fluid sample at a retaining material comprising a porous matrix, wherein the retaining material abuts an end portion of the passage, or wherein the passage at least partly extends into the retaining material, analysing the interstitial fluid sample to measure or detect the presence of one or more analytes/markers.
Description
BRIEF DESCRIPTION OF DRAWINGS
[0036] Exemplifying embodiments will now be described in more detail with reference to the following appended drawings, on which:
[0037]
[0038]
[0039]
[0040]
[0041]
[0042]
[0043] As illustrated in the figures, the sizes of the elements and regions may be exaggerated for illustrative purposes and, thus, are provided to illustrate the general structure of the embodiments. Like reference numerals refer to like elements throughout.
DETAILED DESCRIPTION
[0044] Exemplifying embodiment will now be described more fully hereinafter with reference to the accompanying drawings, in which currently preferred embodiments are shown. The invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided for thoroughness and completeness, and fully convey the scope of the invention to the skilled person.
[0045]
[0046] Generally, there are two main layers of the skin 10: epidermis 12 and dermis 14. Below dermis 14, a third layer of tissue is present; the hypodermis 16 (or subcutaneous tissue). The outermost layer, the epidermis 12, serves as a waterproof barrier enclosing the body of the subject and acts as a protection against infections. The middle layer, the dermis 14, protects the body from external stress and strain, and hosts thermo- and mechanoreceptors. The subcutaneous tissue 16 mainly consists of connective and fat tissue. Its main purposes are to attach the skin to muscles and bones, and to connect nerves and blood vessels to the skin 10. The thickness of the different layers strongly varies across different body locations and between different species, with the overall skin thickness of the human ranging from 0.05 millimetres on the eyelids to more than 1.5 millimetres on the feet soles. Considering the human forearm, the typical location used for example for blood sampling, the average skin thickness is about 1 millimetre.
[0047] ISF is a liquid present in all parts of the body between tissue cells, outside the cells themselves and the blood vessels. Because its similarity with blood plasma, ISF is gaining a growing interest as a monitoring matrix. In particular, skin ISF is very interesting for monitoring applications because of its accessibility. Moreover, the concentration of several bioanalytes is closely correlated to the one in blood, which is typically used as a medical standard. Substances such as glucose, for example, are present in approximately the same concentration as in blood, with just a short physiological delay, quantified in the order of 4 to 12 minutes, due to the diffusion time from the blood capillaries. Additionally, by targeting skin ISF, monitoring is not only potentially achieved in a minimally-invasive fashion, but continues monitoring with transdermal or intradermal devices can also be performed, providing a complete temporal picture of the evolution of the targeted analyte concentration.
[0048] Among the different skin compartments, the dermis 14 has shown to proportionally contain the largest amount and the most homogenously distributed ISF. Thus, the device 100 is preferably configured to allow the tip portion 112 of the micro-needle 110 to be arranged in the dermis 14 when the body 120 is placed on the skin 10 as illustrated in the present figure. However, the device 100 may also be configured to extract ISF from other parts of the skin 10, such as for example the hypodermis 16. The micro-needle 110 may for example protrude about 1 mm from the body 120 of the device 100, which has shown to be suitable for arranging the tip portion 112 in the dermis 14 of the forearm of a human. Further, the tip portion 112 may have a radius of curvature of about 5 μm to facilitate penetration of the skin. The micro-needle 110 according to the present example may be formed of stainless steel, which may reduce the cost compared to for example silicon-based microneedles and allow for standard manufacturing processes for needle cutting and shaping to be used. In the present example the micro-needle 110 is formed from a 32 G stainless steel needle processed by means of a femtosecond laser and cleaned in a 10% citric acid solution in DI water and sonicated, resulting in hydrophilic surfaces.
[0049] The end portion 115 opposite to the tip portion 112 may be arranged within the body 120, preferably in contact with the retaining material 130. The retaining material 130 may for example be arranged to overlap with a meniscus of ISF protruding from the end portion 115 of the micro-needle or be arranged to intersect the flow passageway formed by the lumen 114 of the micro-needle 110. In a further example, shown in for example
[0050] The body 120, in which the micro-needle 110 and the retaining material 130 may be arranged, may be formed by for example a laminate of two or more layers. The body 120 may in an example comprise a base 124 of PMMA, on top of which two 170 μm thick layers of a double-adhesive tape and a plastic foil may be arranged, forming the channel 122 accommodating the retaining material 130. In other examples the body may be formed from silicon processing, moulding or 3D printing.
[0051] The retaining material 130 may be arranged to at least partly fill the channel 122 of the body 120. In the present example, the retaining material 130 is formed of a sheet of grade 238 paper that is processed to obtain a geometry able to store about 1 μl of liquid. An example of such a geometry will be discussed in connection with
[0052] During sampling, the base 124 of the body 120 may be arranged on the skin 10 of the mammal subject such that the tip portion 112 of the micro-needle penetrates the epidermis 12 and proceeds into the dermis 14. ISF of the skin 10 may then flow into the passage 114 of the micro-needle 110 and further into the retaining material 130 in the channel of the body 120, where the ISF sample may be stored. After the sampling, the device 100 can be removed from the skin 10 and stored for subsequent analysis.
[0053] The flow of ISF into the micro-needle may be facilitated or driven by capillary action of the passage 114 of the micro-needle and/or the retaining material 130, or by means of a pressure gradient generated by an applied mechanical pressure or a vacuum suction. An example of a technique employing an applied mechanical pressure will be discussed in the following with reference to the embodiment of
[0054]
[0055] The pressure generating means 200 according to the present example may comprise a rim portion 210, which for example may be ring-shaped and at least partly encircle the micro-needle when placed on the skin 10. This allows for a pressure to be generated, which may converge radially towards the micro-needle to overcome the physiological ISF retention exercised by the skin. The rim portion 210 may form the open end of a casing or housing 200 configured to receive the sampling device 100 of
[0056] It should be noted that the sampling device 100 may be similarly configured as the device 100 discussed in connection with
[0057] In further embodiments, however, a system is envisioned comprising three separate functional components: the device 100 as described above, a pressure generating means comprising a rim portion 210 as illustrated in for example
[0058]
[0059] As indicated in the figure, the micro-needles 110 may be side-opened, i.e., having a passage 114 formed as a trench extending along a side of the micro-needle 110. The trench 114 may extend from the tip portion 112 of the micro-needle to the end portion 115 and fall into a channel 122 which may be common to all the micro-needles 110.
[0060] The channel 112 may comprise a structure 117 for increasing its hydrophilicity. In the present example, such a hydrophilic structure may be formed by a plurality of micropillars 117 protruding from an inner surface of the channel 112. The micropillars 117 may for example be formed when etching the channel 112 and may hence be arranged to protrude from a bottom surface of the channel (i.e., the surface opposing the open wall).
[0061] The device 100 may comprise one or several micro-needle arrays and is not limited to the array 111 and number of micro-needles 110 depicted in the present figure.
[0062]
[0063] The retaining material 130, such as for example a paper configured to absorb ISF, may be arranged in the channel 122 and provided with a shape that conforms with the channel 122. Thus, the amount of ISF that can be held by the paper, i.e., the maximum volume of the ISF sample, may be determined by the shape and size of the retaining material 130, also in case the channel 122 should have a shape differing from the shape of the retaining material 130. During operation, the ISF sample may be extracted by the micro-needle 110 and transported into the channel 122, where it is absorbed by the retention material 130. The progress of the absorption of the ISF sample may be indicated by the liquid front 150 spreading in the channel 122 and moving towards the vent hole 146 and the window 142, where it can be detected either manually by a user or by means of a sensor or detector as illustrated in
[0064] The fill level indicator 140 may further comprise a marking 143 indicating a predetermined fill level, allowing for the user to stop the sampling by removing the device 100 from the skin 10 when the liquid front 150 has reached the marking 143. The marking 143 may for example be arranged such that it is visible through the window 142.
[0065] The geometry for the retaining material, such as a paper strip 130, may together with the fill level indicator 140 be used to ensure that the correct amount of ISF is absorbed before the sampling is stopped. Thus, by verifying that the liquid front 150 has reached the window 142 or marking 143 before the device 100 is removed from the skin 10, it can be assumed that a sufficient amount of ISF is present in the retaining material 130. To further improve quantification, a portion of the retaining material 130 can be used for the subsequent analysis. The portion may for example be selected to include the region closest to the micro-needle to ensure that at least that portion is completely filled with ISF. By selecting the size of the portion with high accuracy, a correspondingly high accuracy of the sample volume may be obtained.
[0066]
[0067]
[0068] Experimental Results
[0069] A device according to an embodiment of the present disclosure was evaluated in a study, which is recited in the following to further exemplify embodiments and possible use of the invention. The device was composed of two main parts: (i) the sampling device 100 similar to the ones described above, and (ii) an inserter, or holder 200, comprising a pressure generating means, or pressure ring, according to the above embodiments. The inserter was used for inserting the micro-needle in the skin and for the generation of a mechanical overpressure facilitating overcoming the physiological ISF retention by the skin to guide the ISF into the micro-needle lumen.
[0070] Volume-metering was provided by the geometry of the retaining material, in this example paper, and by a fill level indicator. In the present example the fill level indicator comprised coloured dye present in the paper itself. During sampling the liquid progressed within the paper matrix transporting the soluble coloured dye. Once the liquid reached the visualization window in the body, the device was removed from the skin.
[0071] The device, also referred to as a microfluidic chip, was designed to collect about 1 μl of ISF. The reliability was characterised in vitro. In most cases, sampling was completed within 5 minutes, with a variation between 3 and 8 minutes. The total number of samplings was in this study 15. The micro-needle insertion was reported as painless by all volunteers, in this case humans. The samples were analysed using liquid chromatography-tandem mass spectrometry (LC-MS/MS), with a similar protocol to the one developed for dried blood spots (DBS) analysis.
[0072] The metering accuracy was evaluated by pumping an artificial ISF solution (phosphate buffered saline solution, glucose, bovine serum albumin, dye) into the microneedle lumen at defined flow rates, which were varied between the different runs. At the time in which the liquid crossed the marking of the visualization window, the flow was stopped, and the total amount dispensed by the toll was recorded. For these tests, a syringe pump was used. The experiments were video recorded using a portable microscope camera.
[0073] To verify the possibility to measure relevant physiological concentration of analytes in small sample volumes by means of embodiments of the present invention, the concentration of caffeine in 1 μl spiked ISF surrogate was measured, as an example of a target molecule. The different concentrations in the various samples were successfully measured using LC-MS/MS, with protocols previously developed for analysis in whole blood from DBS paper.
[0074] For the presented measurements, 1 μl aliquots of dyed artificial ISF with the addition of caffeine at concentrations varying from 0.1 microgram per millilitre (μg/ml) to 9 μg/ml were pipetted into different paper pieces, in duplicates. Samples were then let dry into the paper matrix and stored. The dried samples were then evaluated and characterised using LC-MS/MS. Detection of caffeine was also confirmed in real ISF samples extracted from a human volunteer. Finally, to evaluate the penetration depth and the effect of microneedle penetration into the skin, an optical coherence tool was used.
[0075] The samples were collected on healthy human volunteers. The chosen sampling location was in the inner forearm, having a skin with layer thicknesses allowing access to the dermal region using 1 mm long microneedles. The sampling continued until the indicator was visualised by the operator unless the volunteer decided to interrupt the procedure earlier.
[0076] The volume-metering reliability of the used device was assessed by pumping an ISF surrogate solution into the device at known flow rates until it reached the visualisation window. The minimum and maximum flow rates used were 0.13 μl/min and 0.34 μl/min, respectively. These values correspond to the fastest and slowest sampling rates observed during in-vivo experiments. By imposing a flow rate of 0.13 μl/min, the indicator location was reached after dispensing 1.06 μl, while with 0.34 μl/min, 1.13 μl were dispensed. Therefore, the difference between the minimum and maximum flow rates was within +/−3.5%, with an average collected volume of about 1.1 μl.
[0077] The in-vivo sampling was performed by applying the device to the forearm. In this study, a spring-loaded inserter and a pressuring ring were used to achieve insertion and apply a radial force of about 10 N to lead dermal ISF to the micro-needle opening, respectively. The process was stopped when the liquid front reached the indicator location, in this example the edge of the visualisation window illustrated in
[0078] The insertion speed and the micro-needle geometry may affect the skin penetration process due to the elastic properties of the skin. An OCT image of the needle inserted in the skin was acquired. The skin bending around the needle was approximately 150 μm. The needle opening, starting about 250 μm below the device base, was thus completely inserted inside the skin. One hour after the removal of the needle the pricking location could not be discerned using the OCT tool. The micro-needle insertion was reported as painless by all the individuals. Initially, signs of the skin pricking and the ring pressure were visible at and around the sampling location. The skin recovered within five hours. No permanent mark was visible days after the experiments.
[0079] The results of the experiments recited herein indicate that the embodiments of the present disclosure provide an efficient and minimally invasive technique for sampling ISF from mammal subjects. Compared to prior art techniques, the present device may be simpler, more compact and potentially more cost-effective due to the choice of materials, the fabrication techniques involved, and the lack of complex actuators. Further, the device may be disposable and possible to use with a reusable inserter or holder for facilitating extraction of the ISF sample from the skin.
[0080] The inventive concept has mainly been described above with reference to a few embodiments and examples. However, as is readily appreciated by a person skilled in the art, other embodiments than the ones disclosed above are equally possible within the scope of the inventive concept as defined by the appended claims.